Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe most common GLP-1 tirzepatide side effects are gastrointestinal, including nausea, vomiting, diarrhoea and constipation. They tend to peak in the first days after a new dose or increase, then ease as the body adjusts — usually within one to two weeks. Most people find them manageable; a small number do not. Tirzepatide (sold in the UK as Mounjaro) is a prescription-only medicine, so any decision about managing or continuing treatment sits with your prescriber, not a self-care article. That said, knowing what to watch for makes a real difference to how you get through the early weeks.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: your first Mounjaro pen has arrived, the tracking updated overnight, you've injected into your abdomen as the leaflet describes, and by that evening you feel faintly queasy. That's exactly what most people report. Nausea tops the list of GLP-1 tirzepatide side effects across every trial phase, followed closely by burping, reflux, diarrhoea and constipation, sometimes alternating between the last two in the same week. Fatigue, mild headache and dizziness show up less often but are documented in the same category.
The reason is physiological, not a sign something has gone wrong. Tirzepatide acts on both GIP and GLP-1 receptors, slowing how quickly the stomach empties food into the intestine. That slowing is part of what reduces appetite, but it also means your digestive system is operating differently from usual. For detailed mechanism information, the NHS tirzepatide medicines page covers this clearly at a patient level. The discomfort is usually dullest first thing in the morning and can be eased by eating smaller amounts more slowly, though personal strategies are worth discussing with your prescriber before the next dose is due.
Injection-site reactions, a mild redness or itch at the spot where the pen was used, are also reported. Rotating sites between your abdomen, thigh and upper arm each week helps keep these minor. They rarely need anything beyond a little patience. Full information on how tirzepatide GLP-1 side effects present from the very first administration is covered on our tirzepatide day-one side effects page.
Most tirzepatide side effects are unpleasant but not dangerous. A smaller group are serious enough that acting quickly matters. The one to know by name is acute pancreatitis. In January 2026, the MHRA published a Drug Safety Update specifically highlighting it as an infrequent but serious risk across GLP-1 medicines. The symptom to act on is severe abdominal pain that comes on suddenly, doesn't settle, and may spread through to the back, sometimes with vomiting. If that happens, stop eating and drinking and get urgent medical attention. Do not wait to see if it passes.
Other situations that warrant prompt contact with a healthcare professional include signs of gallbladder trouble (sharp pain in the upper right abdomen, particularly after eating), symptoms of dehydration from a prolonged bout of sickness or diarrhoea, a suspected allergic reaction (swelling around the face, difficulty breathing, a spreading rash), or any sudden changes to your vision. This last one matters particularly for anyone with a background of diabetic eye disease, where rapid changes in blood sugar control can occasionally affect the retina.
Low mood, anxiety or unusual thoughts are also worth flagging without delay. The evidence on whether GLP-1 medicines directly cause mood changes is still being reviewed, but our page on tirzepatide and mood side effects covers the current picture honestly. If you're worried about any symptom and unsure whether it warrants a call, err on the side of contacting someone. Our team is reachable seven days a week via the contact page.
You can also report any suspected side effect to the MHRA directly through the Yellow Card reporting scheme. Reporting is open to patients as well as professionals and helps the regulator build a clearer picture of how medicines behave in real-world use.
Beyond the GI symptoms that most people have heard about, a few tirzepatide GLP-1 side effects tend to come as a surprise. The contraception one is probably the most important to flag early. Because tirzepatide slows gastric emptying, the absorption of an oral contraceptive pill can be reduced during the first four weeks of treatment and for four weeks after each dose step up. NHS guidance is clear on this: add a barrier method (condoms) during those windows. It isn't a concern for patches, rings or coils, only the swallowed pill. There's more detail on the Mounjaro side effects overview if you want to read the full picture before your consultation.
Hair thinning is another thing patients mention, usually around the three-to-six-month mark. It's not listed as a direct pharmacological effect in the same way nausea is, but it's consistent with what happens when calorie intake drops significantly and the body redirects resources. It typically reverses as weight and nutrition stabilise, but it's worth mentioning to your prescriber so they can rule out anything else going on.
Taste changes (food tasting different, or less appealing) are also reported, occasionally to the extent that foods a person previously enjoyed become difficult to finish. This generally fades. And a small number of people notice more vivid dreams or disrupted sleep, though the connection to the medicine versus lifestyle changes happening at the same time isn't fully established. The side effects from tirzepatide page covers these less-discussed experiences in more depth.
None of this is meant to alarm. The clinical trial programme for tirzepatide ran across thousands of adults, the medicine has full MHRA approval for weight management in the UK, and the side-effect profile is well characterised. What varies is the individual, some people sail through the first pen with barely a grumble; others need the titration schedule adjusted or some support with nutrition during the early weeks.
That's exactly why same-day clinical review by a real prescriber matters, not just at the start but before every repeat order. At nume, a GPhC-registered Independent Prescriber reads your consultation responses and checks your progress, they're not rubber-stamping an algorithm's output. If a side effect is getting in the way, that conversation can happen. If you'd like to understand what the full Mounjaro treatment involves before committing, the treatment overview covers eligibility, how the medicine works and what to expect across the dose schedule. For questions about what private treatment actually costs, the Mounjaro pricing page is the straightforward answer.
Side effects are part of the picture, not a reason to avoid seeking help for your weight. If you'd like a prescriber to go through your specific circumstances, including any medicines you already take, starting a free consultation is the next step. No commitment, no upfront payment, reviewed the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.